ABSTRACT
Scaling PD Parameters........................................................................87 3.3.4 Evaluating the Key PK Exposure Parameter that Correlates with
Ef cacy ...............................................................................................88 3.3.5 Establishing the Translatability of Preclinical Models .......................90 3.3.6 PK/PD for Acute Pharmacology Models ............................................ 91 3.3.7 PK/PD for Subchronic Pharmacology Models ...................................93 3.3.8 Challenges in PK/PD Modeling ..........................................................95
